We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Delivering immuno-oncology therapies in the community oncology setting.
- Authors
Brigden, Malcolm; Humphreys, Michael; Imbulgoda, Amal
- Abstract
The increasing availability and wide spectrum of antitumour activity shown by immune checkpoint inhibitors, such as the anti-programmed cell death 1 (anti- PD-1) and anti-PD-1 ligand (anti-PD-Ll) monoclonal antibodies, has produced considerable excitement in the oncology community. While use o f these immuno-oncology (IO) agents may be correlated with good tolerability compared to traditional cytotoxic chemotherapy, their administration may also be accompanied by a different and expanded spectrum of clinical toxicities known as immune-related adverse events (irAEs). Community oncology programs often do not have access to the variety of subspecialty backup available in tertiary cancer treatment centres, and may have other significant operational constraints, including relatively low numbers of personnel. This article details the process undertaken to allow for the successful introduction of these agents into 2 separate community cancer care programs.
- Subjects
CANCER immunotherapy; COMMUNITY health services; CELL death; CANCER chemotherapy; CELL-mediated cytotoxicity
- Publication
Oncology Exchange, 2016, Vol 15, Issue 3, p10
- ISSN
1705-2394
- Publication type
Article